AbbVie Partners With Valkai to Deploy AI in Clinical Research

AbbVie Inc. (ABBV) announced a partnership with life sciences AI platform Valkai on September 29, 2026, to enhance its artificial intelligence infrastructure and accelerate clinical research. Under the agreement, AbbVie will deploy purpose-built AI capabilities across targeted areas of clinical research, aiming to speed insight generation and reduce development timelines. The company said AI complements employee expertise and supports strategic priorities including faster medicine delivery to patients. The partnership builds on AbbVie's existing AI applications across research and development. Financial terms were not disclosed.